<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2858">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471691</url>
  </required_header>
  <id_info>
    <org_study_id>ML27847</org_study_id>
    <nct_id>NCT01471691</nct_id>
  </id_info>
  <brief_title>Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab</brief_title>
  <acronym>RAVEN</acronym>
  <official_title>Phase I/II, Open-label, Study of Intravitreal RAnibizumab 0.5MG, or High Dose 1.0mg for Retinal Vein Occlusions With rEfractory Macular Edema Previously Receiving iNtravitreal Bevacizumab (RAVEN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanscom, Thomas, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hanscom, Thomas, M.D.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines two doses of Ranibizumab (0.5mg and 1.0mg) for the treatment of macular
      edema secondary to retinal vein occlusion in patients that have previously failed treatment
      with other macular edema treatments including bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change From Baseline BCVA</measure>
    <time_frame>Baseline to month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Center Point Thickness</measure>
    <time_frame>months 1-12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Best Corrected Visual Acuity From Baseline</measure>
    <time_frame>months 1-12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With CFT Less Than 300um</measure>
    <time_frame>Month 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess Foveal Thickness</measure>
    <time_frame>Month 6 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Ranibizumab Injections</measure>
    <time_frame>month 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>intravitreal ranibizumab 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>intravitreal ranibizumab 1.0mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab 0.5mg</intervention_name>
    <description>Standard dose</description>
    <arm_group_label>intravitreal ranibizumab 0.5mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab 1.0mg</intervention_name>
    <description>High dose</description>
    <arm_group_label>intravitreal ranibizumab 1.0mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent and comply with study assessments for the
             full duration of the study

          -  Age &gt; 18 years

          -  CRVO or BRVO diagnosis

          -  For CRVO, clinical evidence of perfused central retinal vein occlusion. A CRVO is
             defined as an eye that has retinal hemorrhages and a dilated retinal venous system in
             all 4 quadrants. Other evidence of a CRVO may include telangiectatic capillary bed
             and collateral vessels at the optic nerve head.

          -  Central macular edema present on clinical examination and OCT testing with a central
             point thickness and/or central 1mm subfield thickness &gt; 300 microns after at least 3
             months of bevacizumab or steroid therapy.

          -  Visual acuity score greater than or equal to 19 letters (20/400) and less than or
             equal to 73 letters (20/40) by the ETDRS visual acuity protocol.

          -  Patients must demonstrate that they are no longer improving on bevacizumab or
             intravitreal steroid therapy (i.e. no improvement in acuity in 2 consecutive visits)

          -  BRVO patients treated with grid laser must show residual edema three months following
             latest laser treatment

          -  Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT
             testing and retinal photography

        Exclusion Criteria:

          -  Pregnancy (positive pregnancy test) or known to be pregnant; also pre-menopausal
             women not using adequate contraception.

          -  Participation in another ocular investigation or trial simultaneously

          -  Any condition that, in the opinion of the investigator, would preclude participation
             in the study (e.g. chronic alcoholism, drug abuse)

          -  Significant diabetic retinopathy (greater than moderate NPDR) or macular edema
             associated with diabetic retinopathy

          -  An eye that, in the investigator's opinion, has no chance of improving in visual
             acuity following resolution of macular edema (e.g. presence of subretinal fibrosis or
             geographic atrophy or severe epiretinal membrane)

          -  Presence of another ocular condition that may affect the visual acuity or macular
             edema during the course of the study (e.g. AMD, uveitis, Irvine-Gas)

          -  Evidence of neovascularization of the iris or retina (presence of ischemic CRVO/BRVO)

          -  Evidence of central atrophy or fibrosis in the study eye

          -  Presence of substantial cataract, one that might decrease the vision by 3 or more
             lines of vision at sometime during the study.

          -  History of grid/focal laser or panretinal laser in the study eye in the previous
             three months

          -  History of vitreous surgery in the study eye

          -  History of use of intravitreal, peribulbar, or retrobulbar steroids within three
             months of the study.

          -  History of cataract surgery within 6 months of enrollment.

          -  History of YAG capsulotomy within 2 months of the surgery.

          -  Visual acuity &lt;20/400 in the fellow eye

          -  Uncontrolled glaucoma (pressure &gt;30) despite treatment with glaucoma medications.

          -  History of cerebral vascular accident or myocardial infarction within 3 months prior
             to Day 0.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas O'Hearn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Hanscom AMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Coast Retina</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Retina</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Hanscom AMC</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Coast Retina</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 10, 2015</lastchanged_date>
  <firstreceived_date>November 9, 2011</firstreceived_date>
  <firstreceived_results_date>March 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intravitreal Ranibizumab 0.5mg</title>
          <description>ranibizumab 0.5mg: Standard dose Patients were given six months of monthly treatment with the standard 0.5mg ranibizumab dose, followed by six months of evaluation and PRN treatment based upon pre-specified criteria.</description>
        </group>
        <group group_id="P2">
          <title>Intravitreal Ranibizumab 1.0mg</title>
          <description>ranibizumab 1.0mg: High dose Patients were given six months of monthly treatment with the 1.0mg ranibizumab dose, followed by six months of evaluation and PRN treatment based upon pre-specified criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravitreal Ranibizumab 0.5mg</title>
          <description>ranibizumab 0.5mg: Standard dose</description>
        </group>
        <group group_id="B2">
          <title>Intravitreal Ranibizumab 1.0mg</title>
          <description>ranibizumab 1.0mg: High dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73" spread="5.0"/>
                <measurement group_id="B2" value="78" spread="5.0"/>
                <measurement group_id="B3" value="75" spread="5.0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline BCVA</title>
        <description>Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.</description>
        <time_frame>Baseline to month 6</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intravitreal Ranibizumab 0.5mg</title>
            <description>ranibizumab 0.5mg: Standard dose</description>
          </group>
          <group group_id="O2">
            <title>Intravitreal Ranibizumab 1.0mg</title>
            <description>ranibizumab 1.0mg: High dose</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline BCVA</title>
            <description>Vision was measured using a standard ETDRS chart at baseline and each subsequent monthly visit.</description>
            <units>Letters (ETDRS chart)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14" spread="10"/>
                  <measurement group_id="O2" value="5" spread="6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Center Point Thickness</title>
        <time_frame>months 1-12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Best Corrected Visual Acuity From Baseline</title>
        <time_frame>months 1-12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With CFT Less Than 300um</title>
        <time_frame>Month 6 and 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Excess Foveal Thickness</title>
        <time_frame>Month 6 and 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Ranibizumab Injections</title>
        <time_frame>month 12</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravitreal Ranibizumab 0.5mg</title>
          <description>ranibizumab 0.5mg: Standard dose</description>
        </group>
        <group group_id="E2">
          <title>Intravitreal Ranibizumab 1.0mg</title>
          <description>ranibizumab 1.0mg: High dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ruptured Retinal Macroaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <description>Patient developed breast cancer during trial. It was treated by her oncologist. Not felt to be secondary to Ranibizumab.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas O'Hearn MD</name_or_title>
      <organization>Thomas Hanscom AMC</organization>
      <phone>310-829-3303</phone>
      <email>tohearn@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
